Model N Senior Vice President Jesse Mendelsohn explores the hidden costs and realities of PBM-driven drug pricing and the growing challenges manufacturers face in ensuring contract compliance, formulary access and reimbursement accuracy.
Jesse Mendelsohn
Advertisement
Is senior vice president at Model N, leading its life sciences service division. With more than 20 years in the industry, Mendelsohn is an expert in pharmaceutical pricing, revenue, payer management and government regulation, including Medicaid and state pricing laws.
Articles by Jesse Mendelsohn
Jesse Mendelsohn, executive vice president at Model N, discusses the broader issues impacting drug prices.
Jesse Mendelsohn, executive vice president at Model N, explains the pros and cons of continuing to pursue DTC programs once the government-run program launches.
Jesse Mendelsohn, executive vice president at Model N, discusses how selling drugs directly to patients differs from traditional government programs.
Navigating technology and regulatory shifts in pharma revenue management.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
The Future for Disease Modifying Therapies for Lysosomal Disorders
2
Kardigan Planning for $350 Million IPO Raise: Report
3
How New Technologies Are Impacting the Vaccine Market
4
Zepzelca Fails to Meet Main Goal of Phase III Lagoon Trial in Second-Line Small Cell Lung Cancer
5